-
Mashup Score: 2
Is this earliest of stages a chance to intervene early, or too uncertain to treat?
Source: www.medpagetoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 2Next Up in MS Trials: More Insight Into Progressive Disease - 6 month(s) ago
Neurologist Jeremy Chataway brings you the latest on important clinical trials in progressive MS that will help guide the field toward better treatments.
Source: www.medscape.comCategories: General Medicine News, NeurologyTweet-
Neurologist Jeremy Chataway brings you the latest on important clinical trials in progressive MS that will help guide the field toward better treatments. #MultipleSclerosis https://t.co/RptHIQbVVH https://t.co/hJuyIe1Q0z
-
-
Mashup Score: 2'Frame Running' May Help Boost Physical Activity in MS - 6 month(s) ago
People with multiple sclerosis and moderate-to-severe walking disability could engage in physical activity and improve their physical function with an adapted running frame, suggests new research.
Source: www.medscape.comCategories: General Medicine News, General NewsTweet-
A specially adapted frame to support individuals with walking and balance disabilities could help people with #multiplesclerosis engage in moderate-to-vigorous physical activity and improve their physical function, a pilot study suggests. https://t.co/FZGLZnF581
-
-
Mashup Score: 35Integrin α3 promotes TH17 cell polarization and extravasation during autoimmune neuroinflammation - 6 month(s) ago
Integrin α3 promotes TH17 cell differentiation, proliferation, and transmigration, driving pathogenicity during autoimmune neuroinflammation.
Source: www.science.orgCategories: General Medicine News, Future of MedicineTweet-
To help stem the autoimmune progression of #MultipleSclerosis, new research in mouse models of the disease suggests targeting integrin α3, which is selectively expressed by pathogenic Th17 cells. Learn more in @SciImmunology: https://t.co/9BuSwIu0Ky https://t.co/hlbbbfKwtx
-
-
Mashup Score: 2Integrin α3 promotes TH17 cell polarization and extravasation during autoimmune neuroinflammation - 7 month(s) ago
Integrin α3 promotes TH17 cell differentiation, proliferation, and transmigration, driving pathogenicity during autoimmune neuroinflammation.
Source: www.science.orgCategories: Allergy-Immunology, Latest HeadlinesTweet-
Experiments in mice with a #MultipleSclerosis-like disease revealed that deleting integrin α3 stopped pathogenic Th17 cells from expanding in the central nervous system. @DukeUniversity Learn more: https://t.co/X10Inf50iU https://t.co/2AVomLjnpZ
-
-
Mashup Score: 1Ocrelizumab Benefit Confirmed in Older Patients With MS - 7 month(s) ago
The relapse benefit of ocrelizumab in multiple sclerosis is confirmed for the first time in patients 60 and older starting therapy, say researchers in findings they hope will inform choices.
Source: www.medscape.comCategories: General Medicine News, Latest HeadlinesTweet-
Ocrelizumab effectively prevents relapse in older patients with #multiplesclerosis, researchers have shown for the first time, although the extremely low risk for relapse in this population should be taken into account, they say. https://t.co/adF61dfkcn https://t.co/VkMTFf2lXB
-
-
Mashup Score: 0DMT discontinuation trial halted; MS returned in 17.8% - 7 month(s) ago
It’s still not clear when – or if – certain patients should take a break from MS therapy.
Source: www.mdedge.comCategories: General Medicine News, Latest HeadlinesTweet-
Researchers halted a study into stopping disease-modifying therapy in patients with stable #multiplesclerosis because inflammatory activity returned in nearly one-fifth of subjects who stopped treatment. #ECTRIMS2023 https://t.co/6DsY1quIpG https://t.co/shPadQYWVn
-
-
Mashup Score: 0Ad Hoc Interim Analysis from ENLIGHTEN Clinical Trial of Zeposia for Early RMS Reveals Promising Cognitive Outcomes - Practical Neurology - 7 month(s) ago
In a study presented at the 9th joint meeting of the European and American Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS-A
Source: practicalneurology.comCategories: Latest Headlines, NeurologyTweet-
Cognitive processing speed improved in nearly 50% of people treated with #Zeposia (@bmsnews) for early relapsing #MultipleSclerosis (#RMS) according to an ad hoc interim analysis presented at #MSMilan2023 @ECTRIMS @ACTRIMS. https://t.co/CkduDUVrTf
-
-
Mashup Score: 0New Consensus Statements on Smoldering Disease in Multiple Sclerosis Developed - Practical Neurology - 7 month(s) ago
An international panel has developed consensus-driven statements on smoldering disease (SD) in multiple sclerosis (MS), including domains such as defi
Source: practicalneurology.comCategories: Latest Headlines, NeurologyTweet-
An international panel of experts in #MultipleSclerosis developed new consensus statements on #SmolderingDisease in #MS, which were presented at #MSMilan2023 @ECTRIMS @ACTRIMS. @sanofi https://t.co/2FdUO1LfD2
-
-
Mashup Score: 0CHIMES Clinical Trial Establishes Safety and Efficacy of Ocrevus Treatment in Black and Hispanic Patients with RMS - Practical Neurology - 7 month(s) ago
Interim results from the CHIMES clinical trial (NCT04377555) presented at the 9th joint meeting of the European and American Committees for Treatment
Source: practicalneurology.comCategories: Latest Headlines, NeurologyTweet-
Interim results from the CHIMES trial presented at #MSMilan2023 (@ECTRIMS @ACTRIMS) demonstrated the safety & efficacy of #Ocrevus (@genentech) in treating Relapsing #MultipleSclerosis (#RMS) in Black and Hispanic patients. https://t.co/P3AyyTLthN
-
"The reality is, we just don't know where the beginning is." -- John Corboy, MD, of the University of Colorado, discussing the conundrum of finding what appear to be #multiplesclerosis lesions on an MRI. @MedPageNeuro https://t.co/22fgVaC4ux